MIT mRNA therapeutics spinout Strand has secured series A funding from BeiGene, Redmile Group, Camford Capital, Playground Global and Anri.
Strand Therapeutics, a US-based messenger RNA (mRNA) drug developer spun out of Massachusetts Institute of Technology (MIT), secured $52m in series A funding yesterday.
Biopharmaceutical company BeiGene provided the cash along with hedge fund manager Redmile Group and venture capital firms Camford Capital, Playground Global and Anri.
Founded in 2017, Strand is working on mRNA drugs to treat cancer and other diseases by acting through several mechanisms to attack solid tumours while reducing toxicity to the rests of…
